Fluzoparib

Generic Name: Fluzoparib

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₆F_₄N_₆O_₂

CAS Number: 1358715-18-0

Unique Ingredient Identifier: TWF0ML1CK8

Background: Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

Indication: ⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。

Clinical Trials

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: JS105
Drug: Fulvestrant injection
Drug: Toripalimab Injection
Drug: Pyrotinib Maleate Tablets
Drug: Fluzoparib Capsules
Drug: Paclitaxel for Injection (Albumin Bound)
Drug: Dalpiciclib Isetionate Tablets
Drug: Capecitabine Tablets

First Posted Date: 2024-01-17

Last Posted Date: 2024-03-08

Lead Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.

Target Recruit Count: 306

Registration Number: NCT06208410

Locations: 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Phase 3

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Fluzoparib Capsules
Drug: Apatinib Mesylate Tablets

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 37

Registration Number: NCT06188455

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer
High Grade Serous Adenocarcinoma of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions: Drug: Fluzoparib+Apatinib
Drug: Fluzoparib

First Posted Date: 2023-12-07

Last Posted Date: 2023-12-07

Lead Sponsor: Guangxi Medical University

Target Recruit Count: 80

Registration Number: NCT06161272

Locations: 🇨🇳
Affiliated Tumor Hospital of Guangxi Medical University., Nanning, Guangxi, China

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Phase 2

Not yet recruiting

Conditions: Relapsed Ovarian Cancer

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Jin Li

Target Recruit Count: 54

Registration Number: NCT06081595

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Fallopian-tube Cancer
Ovarian Cancer
High Grade Serous Adenocarcinoma of Ovary
High Grade Endometrioid Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: Fluzoparib Capsules
Drug: Bevacizumab

First Posted Date: 2023-10-02

Last Posted Date: 2023-10-02

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 44

Registration Number: NCT06063070

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, Guangdong, China

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Phase 2

Not yet recruiting

Conditions: PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Interventions: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))

First Posted Date: 2023-09-26

Last Posted Date: 2023-09-26

Lead Sponsor: Chongqing University Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT06055166

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Phase 1

Recruiting

Conditions: Melanoma

Interventions: Drug: Fluzoparib Camrelizumab Temozolomide

First Posted Date: 2023-08-09

Last Posted Date: 2025-03-05

Lead Sponsor: Jun Guo

Target Recruit Count: 50

Registration Number: NCT05983237

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Fluzoparib
Radiation: Preoperative moderately fractionated radiotherapay

First Posted Date: 2023-07-10

Last Posted Date: 2023-07-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT05938374

Locations: 🇨🇳
Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical Center, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma,Soft Tissue
Brachytherapy
Poly(ADP-ribose) Polymerase Inhibitors

Interventions: Drug: Fluzoparib
Procedure: Radioactive particle implantation

First Posted Date: 2023-06-08

Last Posted Date: 2025-05-13

Lead Sponsor: Fujun Zhang

Target Recruit Count: 32

Registration Number: NCT05894018

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Fluzoparib
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen
Drug: Toremifene
Drug: Abemaciclib
Drug: LHRH agonist

First Posted Date: 2023-06-06

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 766

Registration Number: NCT05891093

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy